Approval · Notice of Compliance 29313 · 2022
REZUROCK: Notice of Compliance 29313
Issued October 21, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29313
- Date
- October 21, 2022
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Change in Product Ownership and Product Name Change.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REZUROCK | 02526115 | Marketed |
Medicinal ingredients
- BELUMOSUDIL MESYLATE 200 MG per TAB